Last reviewed · How we verify
Neurotropin
At a glance
| Generic name | Neurotropin |
|---|---|
| Also known as | Drug B |
| Sponsor | VanWorld Pharmaceutical (Rugao) Company Limited |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Neurotropin for Acute Dental Pain and for Chronic Neuropathic Pain (Phase 2)
- Efficacy and Safety of Analgecine for Low Back Pain: a Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial (Phase 3)
- The Clinical Study of Analgecine for the Treatment of Neuropathic Pain (Phase 3)
- Neurotropin Treatment of Fibromyalgia (Phase 2)
- Neuroprotective Effect of Neurotropin on Chronic Oxaliplatin-induced Neurotoxicity in Stage II and Stage III Colorectal Cancer Patients: a Randomized, Double-blind, Placebo-controlled, Parallel Groupi (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neurotropin CI brief — competitive landscape report
- Neurotropin updates RSS · CI watch RSS
- VanWorld Pharmaceutical (Rugao) Company Limited portfolio CI